Search for content, post, videos

BioLamina with partners receive funding of 40 million SEK

BioLamina

BioLamina with partners in the innovation milieu IndiCell receive funding to establish and propel individualized cell therapy treatments in Sweden.

The funded project focuses on an autologous therapy model, in which skin cells are harvested from the patients themselves, then carefully reprogrammed into induced pluripotent stem (iPS) cells in the laboratory, and finally returned to the patient as therapy.

“The gap between cell therapy research findings and commercial stage with clinical manufacturing is very difficult but important to close. IndiCell aims at setting the crucial processes and infrastructure for closing this gap and enabling the innovation projects and necessary competencies to stay within Sweden. BioLamina is part of building some of the core methodological processes and securing innovation management and further commercialization. We look forward to working with the fantastic team!” says Therese Kallur, Director Business Development at BioLamina.

Treatments for Parkinson’s Disease and Macular Degeneration

The aspiring project will implement clinical workflows for stem cell therapy and will first focus on treatments for Parkinson’s Disease and Macular Degeneration. The long-term vision for the innovation milieu is to become a major center for supporting iPS cell-based treatments of various diseases in Sweden. The aim is to ensure that Swedish innovations within regenerative medicine can reach the clinical stage to benefit healthcare and patients.

IndiCell

IndiCell consists of academic scientists with experience in taking advanced cell therapies to the clinic (Lund Universitet, Karolinska Institutet, Kungliga Tekniska Högskolan), the public health care sector (Region Skåne, Region Stockholm), and life science companies (BioLamina AB, AcouSort AB, Lab-On-A-Bead AB). The innovation environment is coordinated by Lund University and led by Professor Anna Falk.

The project is funded for 5-years by the Swedish Agency for Innovation, Vinnova.

Photo: BioLamina